BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 22069160)

  • 1. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
    Peng DX; Luo M; Qiu LW; He YL; Wang XF
    Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.
    Hao X; Zhou Z; Ye S; Zhou T; Lu Y; Ma D; Wang S
    J Huazhong Univ Sci Technolog Med Sci; 2010 Oct; 30(5):620-5. PubMed ID: 21063845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
    BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
    J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer.
    Santibáñez M; Gallardo D; Morales F; López A; Prada D; Mendoza J; Castro C; de León DC; Oñate LF; Perez D; Mohar A; Herrera LA
    Pharmacogenet Genomics; 2013 Apr; 23(4):190-9. PubMed ID: 23407047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-200c and HuR in ovarian cancer.
    Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
    Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
    Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
    Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
    Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
    Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
    Nishimura S; Tsuda H; Kataoka F; Arao T; Nomura H; Chiyoda T; Susumu N; Nishio K; Aoki D
    Hum Pathol; 2011 Apr; 42(4):516-21. PubMed ID: 21237490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.